SOPHiA Genetics reports Q3 earnings; FY22 revenue to be at the low-end of guidance

Nov. 08, 2022 7:25 AM ETSOPHiA GENETICS SA (SOPH)By: Meghavi Singh, SA News Editor
  • SOPHiA Genetics press release (NASDAQ:SOPH): Q3 Non-GAAP EPS of -$0.30.
  • Revenue of $11.6M (+12.0% Y/Y) beats by $0.15M.
  • Adjusted operating loss for the third quarter of 2022 was $19.3 million, compared to $17.0 million for the third quarter of 2021.
  • "We are reaffirming our previously provided guidance of constant currency revenue growth range of 30% to 35% for full-year 2022. We now expect full-year 2022 reported revenue to be at the low-end of our previously provided range of $47.0 million to $49.5 million vs. consensus of $47.73M."

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.